ECS08
EPI SMART, TRUE EPI-ON CORNEAL CROSS-LINKING FOR KERATOCONUS
M. Webb1,*
1CXL Ophthalmics, INC, Burlington, United States
CXL Ophthalmics (CXLO) is developing innovative treatments for corneal diseases with the goal of saving and improving vision for millions of patients around the world. EpiSmart™ is a transformative cross-linking system targeting keratoconus, a common type of corneal ectasia. As a true epi-on procedure, EpiSmart is designed to be minimally invasive without mechanical or chemical disruption of the epithelium, significantly reducing discomfort and recovery time versus current standards of care.
CXLO’s approach will elevate the standard of care for treating keratoconus by enabling treatment upon initial diagnosis, at the earliest stage of disease and the treatment of both eyes simultaneously.
In Q3 of 2022, CXLO raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists. With new ownership, new leadership, and a global health mandate, these new investments will support the advancement of EpiSmart, through Phase 3 trials, beginning in 2023, on the way to a New Drug Application with FDA.
*Please note the company website has been changed since submission.